Drugs / gp140
gp140
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02304185 | Dec 2014 → Apr 2016 | — | Crucell Holland BV | Completed | No outcome recorded |
| Phase 1 | NCT01418235 | Dec 2011 → Oct 2013 | — | HIV Vaccine Trials Network | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-01-18 | Janssen Research & Development, LLC | Results Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial jnj.com ↗
The Mosaico DSMB analysis, based on the data available to date, indicated that the regimen does not protect against HIV and the study is not expected to meet its primary endpoint. |
| 2021-08-31 | Janssen Research & Development, LLC | Results Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗
Data showed the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. |
| 2019-07-23 | Janssen Research & Development, LLC | Results Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen jnj.com ↗
But notably, the study found that bivalent gp140 enhanced immune responses to Clade B, the predominant subtype in the Americas, Western Europe and Australasia. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-01-18 | Janssen Research & Development, LLC | Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial jnj.com ↗ |
| 2021-08-31 | Janssen Research & Development, LLC | Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗ |
| 2019-07-23 | Janssen Research & Development, LLC | Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen jnj.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01418235 ↗ |
| Known as | Glycoprotein 140 | “Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.” NCT02304185 ↗ |
| Known as | Novartis Clade C gp140TV1ΔV2 | “Novartis Clade C gp140TV1ΔV2 with MF59 adjuvant” NCT01418235 ↗ |
| Known as | Novartis V2-deleted subtype C gp140 | “Novartis V2-deleted subtype C gp140 (100 mcg) with MF59 adjuvant” PMID 27583368 ↗ Sep 2016 |
| Modality | Vaccine | “gp140 vaccine” NCT02304185 ↗ |